Synteract says the use of non-validated data systems in clinical trials is a key driver for the ‘rescue study’ segment of the contract research sector.
Scientists from the University of Syracuse’s chemistry department have created a new drug delivery system which they claim will improve the efficacy of cancer-killing drugs.
UK-based Endeavour Specialty Chemicals has launched a range of thioamide intermediates, citing growing evidence of their potential role in development of new cancer treatments.
Late-stage cancer trials are the biggest challenge for pharmaceutical and biotech firms according to data presented at the Biotechnology Industry Organisation's (BIO) CEO and investor conference in Washington DC, US this week.
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Precos is aiming to accelerate growth of its attrition-reducing preclinical oncology screening services by naming a co-founder of ClinPhone as chairman.
Eli Lilly, Merck & Co and Pfizer are combining resources to form the Asian Cancer Research Group (ACRG), a non-profit company which aims to accelerate research into lung and gastric cancers in Asia.
Philips has entered into a joint research programme to evaluate ThermoDox with MR-HIFU, a combination therapy that could provide a precise, non-invasive way to treat difficult cancers.
Source BioScience (SBS) is eyeing acquisitions and investments in technology after it posted a profit in the first six months of 2009, overturning a loss in the same period of last year.
Light Sciences Oncology (LSO) has begun treating the first patient in a Phase I trial of Aptocine (alaporfin sodium), a drug activated by an LED device inserted into a tumour.
Targeted Molecular Diagnostics (TMD), which was acquired by Quintiles in November 2008, has launched two mutation assays to help clients develop more effective, personalised cancer treatments.
Research has been presented on the first Phase I trials of a systemic, non-viral, targeted nanoparticle that delivers a p53 tumour suppressor gene to combat cancer.
Epistem claims its “plucked hair biomarker model” provides drugmakers with minimally invasive way monitoring epithelial response to cancer candidates that can significantly reduce development times.
Two UK-based companies, PRECOS and Argenta Discovery, have pooled their resources in the area of cancer drug discovery to provide services spanning “from hit finding to in vivo proof-of-concept.”
Quintiles Transnational has boosted its array of services for companies developing cancer drugs via the purchase of Illinois, US-based firm Targeted Molecular Diagnostics.
Taiwanese API maker ScinoPharm has been granted a US patent for new crystalline forms of irinotecan which are designed to allow for easier filtration during production processing.
in-PharmaTechnologist.com’s latest round up of developments in drug delivery includes Critical Pharmaceuticals’ sustained release hGH, Phase III results for AP Pharma and nanodiamonds.
AstraZeneca and Singapore’s National Cancer Centre (NCCS) have selected inoperable hepatocellular carcinoma (HCC) as the first target for their new drug collaboration.
Advalytix’ AmpliGrid technology is playing a key role in enabling researchers to discover how just a single cell can lay a huge role in complex biological systems.
German biotech and life science laboratory services firm AgenoLab has installed the first xCelligence real-time cell analysis system to bolster its assay offering to customers.
In an ironic twist, researchers have shown that the tobacco plant, the cause of millions of cases of cancer, can be harnessed to produce personalised cancer vaccines.
US-based Delcath Systems has achieved positive results in treating
diffuse liver cancer using its percutaneous hepatic perfusion (PHP)
delivery system.
The Department of Pathology at Uppsala University Hospital in
Sweden is evaluating Biotage's new pyrosequencing platform to
detect a genetic biomarker that indicates how well a cancer patient
will respond to targetted drug therapies.
AstraZeneca has announced a new collaboration with the University
of Texas' MD Anderson Cancer Center as it steps up its reliance on
external partners.
A team of US researchers have uncovered a cocktail of three drugs
that could be effective at treating every patient with a particular
type of brain cancer that typically has a dismal prognosis.
The creation of a new 'super cell' that can stand firm against one
of the newest types of cancer therapy could shed new light on how
to treat patients if they become resistant to these drugs.
US researchers have developed a fast and inexpensive protein
biomarker detection device that could simplify disease diagnosis
and aid in following disease progression in drug trials.
Japanese drugmaker Astellas has agreed to acquire US biotech firm
Agensys as part of its plan to ramp up antibody research,
especially in the field of cancer.
US-based Aveo Biopharmaceuticals is hoping to prove its R&D
strategy can buck high industry failure rates when trying to design
new cancer drugs and it seems to be working after its lead drug has
passed a first-in-man trial with...
GPC Biotech has met another obstacle in its path towards
satraplatin approval after the German company announced
disappointing and unexpected results in its Phase III trial.
French firm Diatos has created a second generation irinotecan
cancer therapy using its patented peptide-based drug delivery
system, coming up with a drug that has greatly improved efficacy
and safety profile compared to current irinotecan...
German researchers have shown 3D cell structures better resemble
tumour phenotypes than traditional cultures, suggesting they will
make better models for testing new anticancer agents.
GlaxoSmithKline (GSK) has taken a step closer to a true targeted
cancer therapy, and its vaccine, which 'educates' the immune system
to kill tumour cells, has showed 'impressive' results in its latest
clinical...
Britain's Eden Biodesign has been selected by Cancer Research UK as
the beneficiary of two new biomanufacturing contracts as its
biomanufacturing business continues to grow.